| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 58
| Issue : 4 | Page : 262-267 |
|
|
Dexamethasone implant – An update
Richa Pyare, Jyotirmay Biswas
Department of Uvea, Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, Tamil Nadu, India
Correspondence Address:
Dr Jyotirmay Biswas
Department of Uvea, Sankara Nethralaya 18, College Road, Nungambakkam, Chennai - 600 006, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/tjosr.tjosr_75_20
|
|
|
Uveitic entities may be infectious or noninfectious in etiology. Corticosteroids remain the first-line treatment for noninfectious posterior uveitis. Intravitreal injections of steroids have been useful in targeted therapy of the posterior segment. However, a host of systemic and local adverse effects limits the usefulness of steroids. Intravitreal implants of dexamethasone with sustained release of the drug over months are a more effective and safer option. Various formulations with varying dosage and lifespan such as retisert, ozurdex, and yutiq are available. Ozurdex has a very successful track record over numerous studies in treating posterior uveitis in adults and children. It is important to rule out infectious causes of uveitis before administering ozurdex. We can achieve optimal control of ocular inflammation with minimal systemic side effects when used judiciously.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
